New Funding Round Opens for a Universal Muscular Dystrophy Pill
Sacramento, Friday, 24 July 2026.
Sarcomatrix Therapeutics launched a funding round on July 24, 2026, to advance S-969, a daily pill designed to treat Duchenne muscular dystrophy regardless of a patient’s genetic mutation.